Advertisement
Screener

Theravance Biopharma, Inc. (TBPH) Increase (Decrease) in Other Noncurrent Liabilities

2.8 / 5 stars · 68/120 Roast Me

Theravance Biopharma, Inc. Increase (Decrease) in Other Noncurrent Liabilities

Theravance Biopharma, Inc. (TBPH) reported Increase (Decrease) in Other Noncurrent Liabilities of -$69.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-11

  • Theravance Biopharma, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
  • Theravance Biopharma, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was -$69.00K, a 201.47% decline year-over-year.
  • Theravance Biopharma, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$1.00K.
  • Theravance Biopharma, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was -$1.00K, a 125.00% decline year-over-year.
  • Theravance Biopharma, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2025 was $67.00K.
  • Theravance Biopharma, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$532.00K, a 107.05% decline from fiscal 2023.
  • Theravance Biopharma, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was $7.55M.
  • Theravance Biopharma, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2022 was -$525.00K, a 167.57% decline from fiscal 2021.
Period endIncrease (Decrease) in Other Noncurrent Liabilities 3 monthIncrease (Decrease) in Other Noncurrent Liabilities 6 monthIncrease (Decrease) in Other Noncurrent Liabilities 9 monthIncrease (Decrease) in Other Noncurrent Liabilities 12 monthIncrease (Decrease) in Other Noncurrent Liabilities 12 month as first filed
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
-$69.00K
10-Q · filed 2026-08-11
-$70.00K
derived: sum of 3 quarters · filed 2026-08-11
-$71.00K
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31-$69.00K
10-Q · filed 2026-05-07
-$70.00K
derived: sum of 2 quarters · filed 2026-05-07
-$71.00K
derived: sum of 3 quarters · filed 2026-05-07
-$70.00K
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
-$2.00K
derived: sum of 2 quarters · filed 2026-03-23
-$1.00K
derived: sum of 3 quarters · filed 2026-08-11
$67.00K
10-K · filed 2026-03-23
2025-09-30-$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$0.00
derived: sum of 2 quarters · filed 2026-08-11
$68.00K
10-Q · filed 2025-11-12
-$507.00K
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
$69.00K
10-Q · filed 2026-08-11
-$506.00K
derived: sum of 3 quarters · filed 2026-08-11
-$502.00K
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31$68.00K
10-Q · filed 2026-05-07
-$507.00K
derived: sum of 2 quarters · filed 2026-05-07
-$503.00K
derived: sum of 3 quarters · filed 2026-05-07
-$503.00K
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$575.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
-$571.00K
derived: sum of 2 quarters · filed 2026-03-23
-$571.00K
derived: sum of 3 quarters · filed 2026-03-23
-$532.00K
10-K · filed 2026-03-23
2024-09-30$4.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$4.00K
derived: sum of 2 quarters · filed 2025-11-12
$43.00K
10-Q · filed 2025-11-12
$6.29M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$39.00K
10-Q · filed 2025-08-13
$6.29M
derived: sum of 3 quarters · filed 2025-08-13
$7.26M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$39.00K
10-Q · filed 2025-05-12
$6.29M
derived: sum of 2 quarters · filed 2025-05-12
$7.26M
derived: sum of 3 quarters · filed 2025-05-12
$8.05M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$6.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07
$7.22M
derived: sum of 2 quarters · filed 2025-03-07
$8.02M
derived: sum of 3 quarters · filed 2025-03-07
$7.55M
10-K · filed 2025-03-07
2023-09-30$969.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$1.76M
derived: sum of 2 quarters · filed 2024-11-14
$1.29M
10-Q · filed 2024-11-14
$1.19M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$794.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$326.00K
10-Q · filed 2024-08-08
$222.00K
derived: sum of 3 quarters · filed 2024-08-08
-$182.00K
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$468.00K
10-Q · filed 2024-05-15
-$572.00K
derived: sum of 2 quarters · filed 2024-05-15
-$976.00K
derived: sum of 3 quarters · filed 2024-05-15
-$1.00M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31-$104.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01
-$508.00K
derived: sum of 2 quarters · filed 2024-03-01
-$533.00K
derived: sum of 3 quarters · filed 2024-03-01
-$525.00K
10-K · filed 2024-03-01
2022-09-30-$404.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$429.00K
derived: sum of 2 quarters · filed 2023-11-09
-$421.00K
10-Q · filed 2023-11-09
-$420.00K
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$25.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$17.00K
10-Q · filed 2023-08-09
-$16.00K
derived: sum of 3 quarters · filed 2023-08-09
2022-03-31$8.00K
10-Q · filed 2023-05-10
$9.00K
derived: sum of 2 quarters · filed 2023-05-10
2021-12-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$777.00K
10-K · filed 2023-03-01
$587.00K
10-K · filed 2022-02-28
2021-09-30$776.00K
10-Q · filed 2022-11-09
2021-03-31$224.00K
10-Q · filed 2022-05-06
$895.00K
derived: sum of 2 quarters · filed 2023-03-01
$985.00K
derived: sum of 3 quarters · filed 2023-03-01
$1.02M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$671.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$761.00K
derived: sum of 2 quarters · filed 2023-03-01
$792.00K
derived: sum of 3 quarters · filed 2023-03-01
$936.00K
10-K · filed 2023-03-01
-$7.61M
10-K · filed 2021-02-26
2020-09-30$90.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$121.00K
derived: sum of 2 quarters · filed 2021-11-08
$265.00K
10-Q · filed 2021-11-08
$805.00K
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$31.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$175.00K
10-Q · filed 2021-08-05
$715.00K
derived: sum of 3 quarters · filed 2022-02-28
-$4.84M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$144.00K
10-Q · filed 2021-05-06
$684.00K
derived: sum of 2 quarters · filed 2022-02-28
-$4.87M
derived: sum of 3 quarters · filed 2022-02-28
-$4.68M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$540.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
-$5.02M
derived: sum of 2 quarters · filed 2022-02-28
-$4.82M
derived: sum of 3 quarters · filed 2022-02-28
-$4.75M
10-K · filed 2022-02-28
2019-09-30-$5.56M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$5.36M
derived: sum of 2 quarters · filed 2020-11-09
-$5.29M
10-Q · filed 2020-11-09
-$10.20M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30$196.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$269.00K
10-Q · filed 2020-08-10
-$4.64M
derived: sum of 3 quarters · filed 2021-02-26
-$4.64M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31$73.00K
10-Q · filed 2020-05-08
-$4.84M
derived: sum of 2 quarters · filed 2021-02-26
-$4.84M
derived: sum of 3 quarters · filed 2021-02-26
-$11.25M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31-$4.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
-$4.91M
derived: sum of 2 quarters · filed 2021-02-26
-$11.32M
derived: sum of 3 quarters · filed 2021-02-26
-$10.06M
10-K · filed 2021-02-26
2018-09-30-$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
-$6.41M
derived: sum of 2 quarters · filed 2019-11-08
-$5.15M
10-Q · filed 2019-11-08
$5.96M
derived: sum of 4 quarters · filed 2020-02-27
2018-06-30-$6.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05
-$5.14M
10-Q · filed 2019-08-05
$5.96M
derived: sum of 3 quarters · filed 2020-02-27
$13.45M
derived: sum of 4 quarters · filed 2020-02-27
2018-03-31$1.27M
10-Q · filed 2019-05-10
$12.38M
derived: sum of 2 quarters · filed 2020-02-27
$19.86M
derived: sum of 3 quarters · filed 2020-02-27
$20.36M
derived: sum of 4 quarters · filed 2020-02-27
2017-12-31$11.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
$18.59M
derived: sum of 2 quarters · filed 2020-02-27
$19.09M
derived: sum of 3 quarters · filed 2020-02-27
$24.45M
10-K · filed 2020-02-27
2017-09-30$7.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$7.99M
derived: sum of 2 quarters · filed 2018-11-08
$13.34M
10-Q · filed 2018-11-08
$17.57M
derived: sum of 4 quarters · filed 2019-02-28
2017-06-30$505.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02
$5.86M
10-Q · filed 2018-08-02
$10.09M
derived: sum of 3 quarters · filed 2019-02-28
$15.04M
derived: sum of 4 quarters · filed 2019-02-28
2017-03-31$5.35M
10-Q · filed 2018-05-09
$9.59M
derived: sum of 2 quarters · filed 2019-02-28
$14.54M
derived: sum of 3 quarters · filed 2019-02-28
$14.45M
derived: sum of 4 quarters · filed 2019-02-28
2016-12-31$4.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28
$9.18M
derived: sum of 2 quarters · filed 2019-02-28
$9.10M
derived: sum of 3 quarters · filed 2019-02-28
$9.69M
10-K · filed 2019-02-28
2016-09-30$4.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$4.87M
derived: sum of 2 quarters · filed 2017-11-08
$5.46M
10-Q · filed 2017-11-08
$6.54M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30-$82.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
$508.00K
10-Q · filed 2017-08-09
$1.59M
derived: sum of 3 quarters · filed 2018-02-28
$949.00K
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$590.00K
10-Q · filed 2017-05-10
$1.67M
derived: sum of 2 quarters · filed 2018-02-28
$1.03M
derived: sum of 3 quarters · filed 2018-02-28
$1.43M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31$1.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28
$441.00K
derived: sum of 2 quarters · filed 2018-02-28
$843.00K
derived: sum of 3 quarters · filed 2018-02-28
$1.16M
10-K · filed 2018-02-28
2015-09-30-$640.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
-$238.00K
derived: sum of 2 quarters · filed 2016-11-09
$83.00K
10-Q · filed 2016-11-09
$949.00K
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$402.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09
$723.00K
10-Q · filed 2016-08-09
$1.59M
derived: sum of 3 quarters · filed 2017-03-01
$1.59M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$321.00K
10-Q · filed 2016-05-10
$1.19M
derived: sum of 2 quarters · filed 2017-03-01
$1.19M
derived: sum of 3 quarters · filed 2017-03-01
$1.19M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$866.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$866.00K
derived: sum of 2 quarters · filed 2017-03-01
$866.00K
derived: sum of 3 quarters · filed 2017-03-01
$866.00K
10-K · filed 2017-03-01
2014-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12
$0.00
derived: sum of 2 quarters · filed 2015-11-12
$0.00
10-Q · filed 2015-11-12
2014-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13
$0.00
10-Q · filed 2015-08-13
2014-03-31$0.00
10-Q · filed 2015-05-13
2013-12-31$0.00
10-K · filed 2016-03-11
2012-12-31$0.00
10-K · filed 2015-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cryoport, Inc. (CYRX)United States$0.881B-21.29
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Apnimed, Inc. (APMD)United States$0.899B
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71